To establish initial safety and efficacy data of two formulations (Kv9-A /B) in canine soft tissue sarcomas

• All dogs will receive three rounds of the experimental Kv9 treatment, without charge. This treatment has the potential to provide stable disease, which means the tumour doesn’t grow any further. In the case of Kv9 treatment being combined with surgery it has the potential to prevent reoccurrence.

• All dogs in the study will still receive the current normal standard of care, including surgery if elected. The cost of concurrent treatment is the responsibility of the owner.

• Your dog must have a suspected soft tissue sarcoma (must be assessed by a veterinarian)​​ that doesn’t require urgent surgery (>30days).

• They must be expected to survive 3 months minimum.

• The tumour is required to be (approximately) greater than minimum size of 1cm x 1cm and there is no minimum or maximum weight for the animal as long as the tumour is of appropriate size.

• They must not be receiving chemotherapy or immune modulatory drugs (prednisone etc), pregnant or lactating. 

Your dog will undergo screening and planning prior to admittance to the study to determine if they fit the eligibility criteria, this includes blood testing and a tumour sample. There is no charge or cost to you for this.

If enrolled in the study, your dog will receive several small injections (about 0.1mL at each site) of a Kv9 solution directly into their tumour mass every 10-14 days (on three occasions).

In addition, there will be several follow-ups over the next two years to monitor their disease progression (there will be no charge for these follow-up appointments). The study ends after the last monitoring visit.